Gadolinium-enhanced MRI of the abnormal prostate.
A prospective study of the use of a low osmolar gadolinium-based intravenous contrast material for MRI of the abnormal prostate was performed. Eight patients scheduled for prostatectomy, six with prostate cancer and two with benign prostatic hyperplasia (BPH), were imaged preoperatively on a 1.5 T system using a pelvic coil array and employing Gadodiamide (0.3 mmol/kg). T2-weighted fast-spin echo (FSE) imaging was also performed in the same axial planes employed for gadolinium-enhanced studies. Detailed pathologic correlation was performed for the six patients with carcinoma. While regions of BPH and cancer enhanced to a similar degree following intravenous contrast agent, BPH enhancement was more heterogeneous than cancer. No advantages in detecting prostate cancer, in differentiating cancer from BPH or normal prostatic tissue, or in assessing extra-prostatic spread of cancer were observed for the contrast-enhanced studies compared to T2-weighted FSE imaging.